Comparative Pharmacology
Head-to-head clinical analysis: LINEZOLID IN SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LINEZOLID IN SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs MAGNESIUM SULFATE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Linezolid is an oxazolidinone antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing formation of the 70S initiation complex.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
600 mg IV every 12 hours for 10-14 days.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
None Documented
None Documented
Terminal elimination half-life is approximately 5.5 hours; in patients with severe renal impairment (CrCl <30 mL/min), half-life may be prolonged to 7-8 hours.
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Renal excretion accounts for approximately 30% of the dose as unchanged drug; nonrenal clearance (likely hepatic metabolism) accounts for about 70%. Fecal excretion is minimal (<2%).
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Category A/B
Category C
Electrolyte
Electrolyte